Study of rADAMTS13 treatment for congenital TTP
Part of Blood & lymphatic clinical trials.
This study reviews medical records of people with a rare blood clotting disorder called cTTP who received a treatment called rADAMTS13 through an early access program. The goal is to learn more about how the treatment works in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of severe congenital ADAMTS13 deficiency (cTTP).
- You received the study treatment (rADAMTS13) through the early access program.
- You received at least two doses of the treatment.
- You (or your guardian) agree to let researchers review your medical records.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how patients with a rare blood disorder called congenital thrombotic thrombocytopenic purpura (cTTP) are doing while being treated with a replacement therapy called recombinant ADAMTS13. It aims to understand real-world experiences and outcomes.
This study observes children and adults with cTTP who have already used Adzynma. It aims to gather more information about the treatment's real-world effects.
This trial is looking at the immune system's role in thrombotic thrombocytopenic purpura (TTP), a rare blood disorder. It may help researchers understand the condition better and possibly improve future treatments.
This study looks back at medical records of people with immune-mediated thrombotic thrombocytopenic purpura (TTP), a rare blood clotting disorder. It aims to better understand the disease and how it is treated.
This trial tests whether taking aspirin daily can help prevent the blood-clotting episodes (called TTP) caused by a severe lack of a specific protein in your blood. If you have a history of TTP or a genetic form that increases your risk, this study may help reduce those dangerous episodes.
This trial is creating a research database for people with severe ADAMTS13 deficiency, a condition where the body has very low activity of a key blood-protein. It may help researchers better understand the condition by collecting and organizing patient information.
Hear when a new Thrombotic Thrombocytopenic Purpura (TTP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.